COMPANY INFO
Cardurion Pharmaceuticals is a biotechnology company founded in 2017 by physician-scientists Michael E. Mendelsohn, M.D. and Daniel Bloomfield, M.D. The company focuses on developing groundbreaking therapeutics for cardiovascular diseases, particularly targeting heart failure and arrhythmias through innovative clinical programs involving PDE9 and CaMKII inhibition. It is headquartered in Burlington, Massachusetts, with about 50-68 employees, and operates in the biotechnology industry. Their website is https://cardurion.com.
Cardurion Pharmaceuticals is a cutting-edge biotechnology company founded in 2017 by physician-scientists Michael E. Mendelsohn, M.D. and Daniel Bloomfield, M.D. Specializing in cardiovascular diseases, Cardurion Pharmaceuticals is developing innovative therapeutics targeting heart failure and arrhythmias through advanced clinical programs, focusing on PDE9 and CaMKII inhibition. Headquartered in Burlington, Massachusetts, and operating within the biotechnology research industry, Cardurion has approximately 50-74 employees and a strong presence in both the United States and Japan.
Cardurion Pharmaceuticals has established a robust track record in attracting significant venture capital, raising approximately $603.15 million over 6 funding rounds. The company’s funding strategy showcases support from several high-profile investors, with pivotal financial milestones including substantial Series A and B rounds. These funding rounds have been crucial for supporting preclinical and clinical trials, expanding the company’s cardiovascular therapeutics pipeline, and facilitating portfolio growth through asset acquisitions. The consistent participation from leading investors like Bain Capital, NEA, and others underscores a dynamic investment landscape for Cardurion Pharmaceuticals. Their funding journey began with seed and Series A financing to fuel early pipeline development, followed by larger venture rounds to push candidates through late-stage clinical trials.
The Series B financing round was designated to support later-stage clinical trials for Cardurion Pharmaceuticals’ two lead drug candidates, CRD-750 (PDE9 inhibitor) and CRD-4730 (CaMKII inhibitor). Additionally, funds are allocated to expand portfolio indications, progress internal discovery programs, and acquire further cardiovascular assets for broader market impact.
This round built on earlier achievements to advance preclinical trials and continue developing the cardiovascular therapeutics pipeline. The infusion supported Cardurion Pharmaceuticals in transitioning novel treatments toward clinical proof of concept.
The initial Series A round provided startup capital for Cardurion Pharmaceuticals, enabling its launch and early development of a pipeline targeting unmet needs in cardiovascular disease.
As the lead investor in Cardurion Pharmaceuticals' Series B round, Ascenta Capital has played a key role in supporting the company’s growth trajectory and clinical trial expansion. Their involvement signifies strong support for Cardurion’s late-stage pipeline.
A major venture capital firm, New Enterprise Associates participated in Cardurion Pharmaceuticals funding rounds, providing critical investment support for ongoing research and development.
Repeatedly funding Cardurion Pharmaceuticals across several rounds, Bain Capital stands out as a significant and recurring backer. Their sustained investments have been pivotal in advancing the company’s research and expansion efforts.
As the lead investor in the Series A1 round, Polaris Partners provided early-stage support that was instrumental in helping Cardurion Pharmaceuticals establish its core cardiovascular pipeline.
A participant in the Series B investment, Blue Owl Capital supports innovative healthcare ventures and has contributed significant capital to Cardurion Pharmaceuticals’ growth and R&D.
Delos Capital Partners led the Series A2 round, enabling Cardurion Pharmaceuticals to progress its preclinical work and expand its pipeline of cardiovascular disease treatments.
An active investor in the biotech space, Digitalis Ventures has contributed funding in support of Cardurion Pharmaceuticals' mission to address critical needs in cardiovascular medicine.
Known for its strategic investments in advanced therapeutics, Farallon Capital Management has supported Cardurion Pharmaceuticals as it advances drug candidates through the clinical pipeline.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Cardurion Pharmaceuticals funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.